The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck; Merck; Merck; Merck
Stock and Other Ownership Interests - Merck; Merck; Merck; Merck
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study.
 
Aurelien Marabelle
Stock and Other Ownership Interests - PEGASCY; PEGASCY; PEGASCY; PEGASCY
Honoraria - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merieux Nutrisciences; Merieux Nutrisciences; Merieux Nutrisciences; Merieux Nutrisciences; Oncovir; Oncovir; Oncovir; Oncovir
Consulting or Advisory Role - AMGEN; AMGEN; AMGEN; AMGEN; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bioncotech; Bioncotech; Bioncotech; Bioncotech; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; CERENIS THERAPEUTICS; CERENIS THERAPEUTICS; CERENIS THERAPEUTICS; CERENIS THERAPEUTICS; Eisai; Eisai; Eisai; Eisai; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; ImCheck therapeutics; ImCheck therapeutics; ImCheck therapeutics; ImCheck therapeutics; Innate Pharma; Innate Pharma; Innate Pharma; Innate Pharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Lytix Biopharma; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Molecular Partners; Molecular Partners; Molecular Partners; Molecular Partners; MSD; MSD; MSD; MSD; NOVARTIS; NOVARTIS; NOVARTIS; NOVARTIS; OSE Immunotherapeutics; OSE Immunotherapeutics; OSE Immunotherapeutics; OSE Immunotherapeutics; Partner Therapeutics; Partner Therapeutics; Partner Therapeutics; Partner Therapeutics; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Redx Pharma; Redx Pharma; Redx Pharma; Redx Pharma; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER; Sotio; Sotio; Sotio; Sotio; Symphogen; Symphogen; Symphogen; Symphogen
Speakers' Bureau - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche
Research Funding - Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MERUS (Inst); MERUS (Inst); MERUS (Inst); MERUS (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Transgene (Inst); Transgene (Inst); Transgene (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University); monoclonal antibodies against CD81 (Stanford University); monoclonal antibodies against CD81 (Stanford University); monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche
Other Relationship - PEGASCY; PEGASCY; PEGASCY; PEGASCY
 
Philippe Alexandre Cassier
Honoraria - Amgen; Amgen; Amgen; Amgen; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Janssen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Loxo (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst); Transgene (Inst); Transgene (Inst); Transgene (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Netris Pharma; Netris Pharma; Netris Pharma; Netris Pharma; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Speakers' Bureau - Amgen; Amgen; Amgen; Amgen; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
 
Tormod Kyrre Guren
No Relationships to Disclose
 
Antoine Italiano
Honoraria - Bayer; Bayer; Bayer; Bayer; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Epizyme; Epizyme; Epizyme; Epizyme; Lilly; Lilly; Lilly; Lilly; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Epizyme; Epizyme; Epizyme; Epizyme; Immune Design; Immune Design; Immune Design; Immune Design; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche
Research Funding - AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; PharmaMar; PharmaMar; PharmaMar; PharmaMar; Roche; Roche; Roche; Roche
 
Steven Chuan-Hao Kao
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche; Roche; Roche; Roche
 
Dorte Nielsen
No Relationships to Disclose
 
Paolo Antonio Ascierto
Stock and Other Ownership Interests - PrimeVax; PrimeVax; PrimeVax; PrimeVax
Consulting or Advisory Role - 4SC; 4SC; 4SC; 4SC; Alkermes; Alkermes; Alkermes; Alkermes; Amgen; Amgen; Amgen; Amgen; Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Genmab; Genmab; Genmab; Genmab; Idera; Idera; Idera; Idera; Immunocore; Immunocore; Immunocore; Immunocore; Incyte; Incyte; Incyte; Incyte; MedImmune; MedImmune; MedImmune; MedImmune; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Sandoz; Sandoz; Sandoz; Sandoz; Sanofi; Sanofi; Sanofi; Sanofi; Sun Pharma; Sun Pharma; Sun Pharma; Sun Pharma; Syndax; Syndax; Syndax; Syndax; Ultimovacs; Ultimovacs; Ultimovacs; Ultimovacs
Research Funding - Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
Giovanni M. Bariani
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Mabxience; Mabxience; Mabxience; Mabxience; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme
 
Armando Santoro
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; MSD; MSD; MSD; MSD; Pfizer; Pfizer; Pfizer; Pfizer; SERVIER; SERVIER; SERVIER; SERVIER
Speakers' Bureau - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; ArQule; ArQule; ArQule; ArQule; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; Sandoz; Sandoz; Sandoz; Sandoz; Servier; Servier; Servier; Servier; Takeda; Takeda; Takeda; Takeda
 
Manisha H. Shah
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Ignyta; Ignyta; Ignyta; Ignyta; Loxo; Loxo; Loxo; Loxo; Novartis; Novartis; Novartis; Novartis
Research Funding - Eisai; Eisai; Eisai; Eisai; Loxo; Loxo; Loxo; Loxo; Merck; Merck; Merck; Merck
 
Jamil Asselah
Consulting or Advisory Role - Roche Canada; Roche Canada; Roche Canada; Roche Canada
Research Funding - Celgene; Celgene; Celgene; Celgene
 
Anthony B. El-Khoueiry
Honoraria - Agenus; Agenus; Agenus; Agenus; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Agenus; Agenus; Agenus; Agenus; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; CytomX Therapeutics; Eisai; Eisai; Eisai; Eisai; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Roche; Roche; Roche; Roche
Research Funding - Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; Astex Pharmaceuticals; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Merck; Merck; Merck; Merck
 
Kristen Renee Spencer
No Relationships to Disclose
 
Shunji Takahashi
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; MSD; MSD; MSD; MSD; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Novartis; Novartis; Novartis; Novartis; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Novartis; Novartis; Novartis; Novartis
 
Arkendu Chatterjee
No Relationships to Disclose
 
Fan Jin
Employment - Merck; Merck; Merck; Merck
Stock and Other Ownership Interests - Merck; Merck; Merck; Merck
Travel, Accommodations, Expenses - Merck; Merck; Merck; Merck; Merck; Merck; Merck; Merck
 
Kevin Norwood
No Relationships to Disclose
 
Jean-Pierre Delord
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); Genentech (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst); MSD Oncology (Inst)